These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19122269)

  • 1. [New development in bisphosphonate treatment. Bisphosphonates and gastrointestinal adverse effects].
    Miki T; Masaki H
    Clin Calcium; 2009 Jan; 19(1):91-7. PubMed ID: 19122269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.
    Carlson ER; Basile JD
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):85-95. PubMed ID: 19371819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New development in bisphosphonate treatment. Treatment with bisphosphonates for cancer-induced bone disease].
    Abe M
    Clin Calcium; 2009 Jan; 19(1):55-62. PubMed ID: 19122265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development and relapse of gastroduodenal ulcer in patients taking nonsteroid anti-inflammatory drugs: effects of standard risk factors].
    Karateev AE; Nasonova VA
    Ter Arkh; 2008; 80(5):62-6. PubMed ID: 18590118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?
    Cryer B; Bauer DC
    Mayo Clin Proc; 2002 Oct; 77(10):1031-43. PubMed ID: 12374247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the gastrointestinal effects of the nitrogen-containing bisphosphonates pamidronate, alendronate, and olpadronate in humans.
    Twiss IM; van den Berk AH; de Kam ML; Bosch JJ; Cohen AF; Vermeij P; Burggraaf J
    J Clin Pharmacol; 2006 Apr; 46(4):483-7. PubMed ID: 16554458
    [No Abstract]   [Full Text] [Related]  

  • 8. [Adverse events of drugs for the treatment of osteoporosis].
    Nakamura T
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():304-10. PubMed ID: 18074553
    [No Abstract]   [Full Text] [Related]  

  • 9. [Nonsteroidal-anti-inflammatory drugs and serious undesirable gastrointestinal effects].
    Fabijanić D; Kardum D; Banić M; Fabijanić A
    Lijec Vjesn; 2007; 129(6-7):205-13. PubMed ID: 18018712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of patients on bisphosphonates and prevention of bisphosphonate-related osteonecrosis of the jaw.
    Chu V; ;
    Hawaii Dent J; 2008; 39(5):9-12; quiz 17. PubMed ID: 19189512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies.
    Assael LA
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):35-43. PubMed ID: 19371813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications.
    Lanas A; Sopeña F
    Gastroenterol Clin North Am; 2009 Jun; 38(2):333-52. PubMed ID: 19446262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of bisphosphonates in the treatment of osteoporosis.
    Recker RR; Lewiecki EM; Miller PD; Reiffel J
    Am J Med; 2009 Feb; 122(2 Suppl):S22-32. PubMed ID: 19187809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate use and health history questionnaire.
    Dao V; Kraut RA
    N Y State Dent J; 2008 Nov; 74(6):20-2. PubMed ID: 19195232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Necrotic actions of nitrogen-containing bisphosphonates and their inhibition by clodronate, a non-nitrogen-containing bisphosphonate in mice: potential for utilization of clodronate as a combination drug with a nitrogen-containing bisphosphonate.
    Oizumi T; Yamaguchi K; Funayama H; Kuroishi T; Kawamura H; Sugawara S; Endo Y
    Basic Clin Pharmacol Toxicol; 2009 May; 104(5):384-92. PubMed ID: 19413658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diabetes mellitus and bisphosphonate-related osteonecrosis of the jaws].
    Urade M
    Clin Calcium; 2009 Sep; 19(9):1332-8. PubMed ID: 19721206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upper gastrointestinal complications associated with NSAIDs in children.
    Autret-Leca E; Bensouda-Grimaldi L; Maurage C; Jonville-Bera AP
    Therapie; 2007; 62(2):173-6. PubMed ID: 17582320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma?
    Siddiqi A; Payne AG; Zafar S
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep; 108(3):e1-8. PubMed ID: 19570696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.
    van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment with bisphosphonates and previous dental health].
    Madrid C; Bouferrache K; Jaques B; Broome M
    Rev Med Suisse; 2009 Apr; 5(200):909-10; author reply 910-1. PubMed ID: 19438092
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.